Role of IGF-I in aspirin pretreatment in streptozotocin induced type-II diabetic rats

In the present study, we made an attempt to investigate role of insulin like growth factor-I (IGF-I) in aspirin pretreatment in streptozotocin induced type-2 diabetes mellitus in rats. Rat pups were divided in to four groups, on 5th day of their birth, group-I pups were received citrate buffer solution served as normal, group-II were treated only with streptozotocin (80mg/kg, i.p) served as diabetic, group-III & group-IV were treated with aspirin (10mg/kg/day, p.o) for one month (5-35 days) and two month (5-65) after streptozotocin served as treated groups. On 36 and 66 day, blood samples were collected from all animals and fasting blood sugar, fasting insulin, IGF-I, insulin resistance and insulin sensitivity levels were estimated. Results of 36 & 66 days blood samples of pups treated with streptozotocin alone and in combination with aspirin for one month and two months were shown significantly raised body weight, fasting blood glucose and insulin resistance levels (P=0.0005, p<.0001, p<.0001, P=0.0006, p<.0001, P=0.0030) and significantly lowered fasting insulin and insulin sensitivity levels when compared to the normal control pups (p<.0001, p<.0001, p<.0001, p<.0001, p<.0001, P=0.0068) respectively. Pups treated with aspirin for one month were shown significantly raised IGF-I levels but two months treatment were shown significantly lowered IGF-I levels when compared to the normal pups (p<.0001). The present study indicates that aspirin pretreatment seems to protect pancreas from damage caused by STZ and maintains glucose levels in diabetic rats and increases insulin sensitivity and reduces insulin resistance, this may a involvement of insulin like pathway particularly IGF-I.